



Huons Global

Investor Relations

1Q. 2021

Disclaimer

All information in this book including business performance and financial report is written by Korean-International Financial Reporting Standards(K-IFRS) .

This book includes a “forecast” about future. It is not about the past, but the future business plan including expected management status and financial performance, and sometimes there can be word such as ‘anticipation’, ‘forecast’, ‘plan’, ‘expectation’, and ‘(E)’.

A “forecast” often means uncertain factors which can affect the company either positively or vice versa, and those can include:

- Domestic or international financial market trends including fluctuation of foreign exchange rate or interest rate.
- Company’s very important strategic decision such as M&A
- Unexpected business environment change in the main industry
- Other internal and external change that can affect the company’s management and finance.

Because of those uncertain risks, company’s actual business performance can be different from the “forecast” in this booklet. Also the information we provide is written as of the day we deliver the presentation, so it can be changed due to unexpected external status of industry or internal company’s revision of strategies without any prior notice in the future.




Huons Global

Contents

- 1 Introduction**
- 2 Business Results**
- 3 Subsidiary**
- 4 Financial Statements**

“Total Healthcare Group includes Pharma, Medical devices, Cosmetics, and Health functional food”





Sung-Tae Yoon

**Vice Chairman
C.E.O**

C.E.O of Huons Global

IBM Korea

MS Project Mgt. at
Hanyang Univ.

W. Paul Kim

President

Director of Huons Global

BMS/GSK/AkzoNobel

MIT Scientist

PhD Biology at
Korea Univ.

MSc in CANADA

Bo-Young Yoon

**President
Head of Financial
Mgt. Support
Division**

Head of Financial Mgt.
Support Division

Jeil Pharmaceutical
Co., Ltd.

BA Business
Administration
At Dongguk Univ.

Kyu-Rae Lee

**Director
Outside Director**

Family Medicine Doctor
at
East Inccheon Gil Hospital

Head of Medical
Examination Center at
Baptist Hospital

Doctor of Medicine at
Yonsei Univ.

Byung-Hoon Tak

**Director
Outside Director**

Commander of Seoul
Police Department

BS Fine Chemistry at
Seoul National
Univ. of Science &
Technology




“Continuous improvement from affiliated companies’ growth”

[Consolidated]

(Unit: Billion KRW, %)

(Unit: Billion KRW, %)



[Seperate]

(Unit: Billion KRW, %)

	2018	2019	2020	2020.1Q	2021.1Q	YoY
Sales	27.9	29.6	41.9	14.5	14.6	+1.1%
Operating income	11.6	9.1	15.1	7.4	6.7	-8.8%
Net income	10.8	9.9	14.8	6.7	6.7	+0.2%



Global Sales


- Received approval of "Hutox" for export license (Oct. 2016)
- Export to **South-East Asia, Middle East, Latin America**



Domestic Sales

- Launched 'Liztox' in domestic market (Jun. 2019)

Oversea HUTOX status



국가	계약 체결일	국가	계약 체결일
Kuwait	2018.05	Singapore Malaysia	2019.03
Brazil Ukraine	2018.06	Dominica Uzbekistan and other CIS 5 countries	2019.06
Russia	2018.07		
Lebanon	2018.08	Pakistan	2019.08
China	2018.09	Bolivia Colombia	2019.09
Japan	2018.11	Panama Nicaragua	2019.12
Turkey	2019.02	Thailand	2020.04

Expansion of “Hutox” Indications & Development of Low Molecular Botulinum Toxin Product

**Hutox
Indication
Expansion**

Crow’s Feet lines (Approved in 1Q 2021)

 **“Expansion of Therapeutic Indication”**

Upper limb spasticity
(Completion date of clinical trial(phase I) in 4Q. 2020)

Benign Masseteric Hypertrophy
(On-going of clinical trail ‘Phase II’ studying in 1Q.2021)

**Low
Molecular
Botulinum
Toxin
product**

 **“150kDa”**: Low molecular Botulinum toxin that lowers immunogenicity compared to the 900kDa of original product

2020.4Q Completion of clinical trial(phase I) of Glabellar Lines

**Diverse
Manufacturing
unit**



Submission of NDA application for 50unit / 200unit on Sep. 2020.
√ 50unit approved in Jun.2021



R&D PIPELINE

Category	Code	Indications	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Registration	
Biological Products	HBPB1-001 (90 OKDa)	Glabellar lines	[Progress bar spanning Discovery to Phase III]						
		Crow's Feet Lines	[Progress bar spanning Discovery to Phase III]						
		Post stroke-Upper Limb Spasticity	[Progress bar spanning Discovery to Phase I]						
		Benign Masseteric Hypertrophy	[Progress bar spanning Discovery to Phase II]						
	HBPB1-002 (15 OKDa)	Glabellar lines	[Progress bar spanning Discovery to Phase I]						
	HBPB3-003	Cellulite	[Progress bar in Discovery]						



Pharma(ETC)

- Medications that require prescription
- Multiple items(eye drops, injections etc.)
- A comprehensive portfolio covering various fields




CMO

- Produce medications using Huons' Plant
- Customers : Domestic and foreign pharmaceutical companies



Beauty·Well-being·Other

- Medicines and others for health maintenance
- Expanding portfolio to related items
- Well-being / Obesity / Pain / Botulinum Toxin / Health Functional Food / Medical appliance




※ Sales % in 1Q.2021



“Sustaining Solid Sales Growth & Stable Profit”

(Unit: Billion KRW)

- Pharma
- Beauty/Well-being/Other
- CMO
- Operating Income
- Net Income



















[Consolidated]

	2018	2019	2020	20 1Q	21 1Q
Sales	329	365	407	95	100
Operating Income	45	48	54	11	14
Net Income	45	37	57	10	9

Next generation growth strategy “Open Innovation”

- Signed joint research agreement with companies in various fields
- Goal of acquiring next generation growth engine through joint R&D

Exclusive right of Sales in domestic	Joint R&D MOU	
 Insulin Pump  Biosimilar  Bladder Cancer Treatment  Peptide medicine  MRgFUS  Peptide medicine	 Artificial cornea development  Antibacterial/Antiviral treatment  Proteolysis-Targeting Chimaera New medicine for heart failure  Health functional food  Microbiome medicine & Health functional food  Natural medicine & Health functional food  Health functional food  Electronic medicine  Natural medicine & food  AI based New treatment	

New R&D Theme



- CNS – Social anxiety Treatment
- Eye diseases(Presbyopia, myopia) Treatment
- Medical device for treating bladder cancer
- Cancer – Diagnosis, Treatment, Assistance



Bladder cancer treatment (TSD-001) with

- TSD-001 : Expect 1st FDA approval of treatment for Non-Muscle Invasive Bladder Cancer(NMIBC)
- In 2020, Clinical trial 1/2A in USA completed, global **Clinical Phase 2B/3** are planned in 2021
- Goal is to release it in 2024 (Global Market)


Current Standards of Care (SOC): Adjunct intravesical therapies are used post surgery to reduce occurrence of NMIBC



Development of Synthetic New Drugs




Heart Failure



Nature, vol. 26, pages 416-417 (2015)

- Develop a synthetic new drug that can improve heart failure symptoms by controlling cGMP and PKGI activities that protect the heart
- **Selection of candidate materials in 2021**

Fatty liver



- Based on **PROTAC(Proteolysis-targeting chimaera)**
- Development of a drug that can improve the symptoms and control progress of liver disease by removing the target protein that causes liver disease
- **Securing leading materials in 2021**

Menolacto Probiotics



- 2019. 10 Certified as a Functional Ingredients (Authorized function : Help menopausal women’s health)
- **2020. 04 elruby Menolacto probiotics product released**
- Korea’s first and only one female menopausal health improvement Individually recognized Probiotics
- Deposit germ at KMCC(KCCM11808P) : *L.acidophilus* YT1
- Registered as Korean Patent, and Applied for Patents in US/EU/Japan(Co-develop with KFRI)


Improvement for menopause

- 1) Identify the improvement for Kupperman index, KMI)
- 2) Confirm the significant improvement for Modified KI
- 3) Confire the improvement for MENQOL




Develop ingredients for improving Prostate Health

- Application functionality : Prostate Health
- Apply for Korean Patent
- Submission of approval application as a ingredient(Jan. 2020)




Everything You Need To Know About Benign Prostatic Hyperplasia
 June 25, 2018/in Blog /by Georgia UrologyBy Dr. Lewis S. Kriteaman



ExAblate[®] Neuro with INSIGHTEC

- World's first Incisionless Surgery platform which uses focused ultrasound with submillimeter accuracy to treat deep in the brain— all without making a single incision.
- Only focused ultrasound device with FDA approval to treat in the brain
- Operates in 60 major hospitals around the world including US, Europe and Asia
- Current indications – essential tremor, tremor-dominant Parkinson's disease



CGMS

- Targeting to build Diabetes portfolio and expand market by introducing new medical devices
- Start paying health insurance benefits only for Type 1 diabetes
 - ① Since Jan. 2019 : Sensor
 - ② Since Jan. 2020 : Transmitter

Dexcom G5



New

Dexcom G6



Measures glucose in 5-minute intervals → Measures, trend arrows & graphs, help with treatment decision with alarm



- 1 Sensor for 7 days, 1 transmitter for 3 months


- 1 Sensor for 10 days, 1 transmitter for 3 months
- Improving patient convenience(One touch Sensor)
- Approved KFDA(Mar. 20), Released Oct. 20



Wearable Insulin Pump with



- 1st patch type insulin pump in Korea
- Easy to carry and to use
- **Achieved approval(Jun. 19) → Complete Clinical Trial(2H. 20) → Launch(2021)**
- 1 patch for 3.5 consecutive days



[Business Lines]

Filler
26% of sales

- High purity HA ingredient
- High purity HA raw material refinement sales rise
- Superior viscosity/elasticity/durability
- Registered in NMPA (Mar. '15)
- Export manufacturing techniques to Sesderma in Spain(Nov.'18)

Arthritis
10% of sales

- Exported the technique of 1 shot arthritis medication to China
- Humiaju®: Approved as an once injection type
 - ⇒ For joint synovia (HA ingredient)
 - ⇒ Strengthen exercise capacity, Less pain

Pharma, CMO
36% of sales

- Approved PDRN injection 'Revitalax' in Apr. 2018, MFDS.
 - ⇒ Entered into regenerative medicine market
- Ethical drugs (anemia, internal secretion, and etc.)
- Exported 'COVID-19' Rapid Diagnostic Kit

Cosmetics, Others
28% of sales

- "Derma Elravie' Brand marketing
- Functional cosmetics (HA specialty)
 - ⇒ wrinkle care, whitening, and etc.
- Expansion for Chinese cosmetic market with CKH Health Corp.




“Sales growth & Profit improvement”

[Consolidated]

■ Operating income

■ Profit

(Unit : Billion KRW)



[Separate]


	2018	2019	2020	2020 1Q	2021 1Q
Revenue	58	69	80	17	22
Operating income	8	9	12	2	3
Profit	8	9	13	1	3

Filler + Medical devices + Botulinum Toxin → Competitive power

Sales Package



Diversified product portfolio



HA Diversification

PDRN
(PolyDeoxyRiboNucleotide)

Volumizing Filler

Filler for Urinary system

**PN Joint injection,
PN Eye drops**

HA based/ natural polymers
 Diversified materials
 Clinical trial phase III completed (3Q 2018)
 Final approval (1Q 2019)

Highly improved safety
 Verified safety/efficacy by clinical trial
 - Clinical trial phase III completed (4Q 2018)
 - Expected final approval (1Q 2020)

Apply for high purity nucleic acid naturally derived
 - medicines, filler, cosmetics
 Extract high-purity nucleic acid From salmon testis
 PDRN raw materials: KFDA(2Q 2018)
 PN Joint injection : Clinical trial approval(3Q 2020)

Expectations

Expectations

Expectations

Improved safety
 - Reduced HA, Cross-linker
 Volumizing effect on face
 - High viscosity/elasticity/persistence

Expand HA Filler market from new indications

Reduced wound healing time
 Accelerate collagen/cell differentiation
 Blood vessel endothelial proliferation factor induction

- Produce & Sales medical disinfectant, disinfectants and sterilizer
- Produce & Export Auto endoscope reprocessors

◆ Antiseptic products


- Hemoclean (exclusive for artificial kidney, US FDA/EU CE certification)
- Scotelin, Ophiclean, TeraClean (endoscope instrument sterilization)
- TBXzyme (intermediate-level disinfection for skin & hard-surface)
- Hexywipes
(OTC, antiseptic body/hands tissue as CHG 2%, 4%)

◆ Medical sterilizers

- MTW-01 (minimal function, Target on regional clinic)
- **"HUEN Single" get domestic permission in Jun 2020**
- **"Single use and discard" system**
(Target on single use, general hospital, overseas market)
- "HUEN Single" under overseas registration

◆ Space sterilizers

- **Sterilizer "IVH ER" is authorized by CE(EU) in Mar 2021**
(KC(Korea), CQC(China) are expected additionally)
- Increasing demand on sterilization, prevention for medical infection
(pharmaceutical GMP, hospital, food maker etc.)
- Nano-sized vapor spray and High level safety



Scoterin(percetic acid)



Ophiclean(OPA)



Space sterilizer 'HUEN IVH'
(spray sterilant & sterilize)



Scrubber
(absorb sterilant & remove)



MTW-01(Reuse)



HUEN Single shot
(single use)

Plan

- Medical sterilizer "Huen Basic" is expected to be authorized by CE(EU) and CFDA(China)


- A specialized medical glass container (ampule, vial, and cartridge) manufacturer & supplier
- As a front-runner in the glass packing industry, merged Suju Science (lab experiment and analytic tools business), become a total solution company for supplying glass containers and raw/subsidiary materials

Ampule

Item	Raw materials standard: 10.0~24.5Ø , Production standard: 1.0cc ~ 20.0cc
Feature	<ul style="list-style-type: none"> ▪ Type: Pattern C (ISO 9187-1) ▪ Cutting: One point cutting (OPC ISO 9187-2), color brake, score brake

Vial & Cartridge

Item	Raw materials standard: 8.65Φ ~ 50.0Ø , Production standard: 1.0cc ~ 100.0cc
Feature	<ul style="list-style-type: none"> ▪ Type : Injection (ISO 8362-1), Screw (ISO 11418-7), Blow back, Freeze drying



Take-over Suju Science

- Taking over was finished in Jan.2019
 - ☞ Sales of 2019 : 1.6 bil KRW, 2020 : 3.3 bil KRW, 2021.1Q : 1.1 bil KRW
- Expected enhancement of sales growth by constructing sales agencies by regions
- Opened online shopping mall via website: for the ease of use for customers

- Hold 7 types of biological drugs' pipelines
- Research and develop new peptide and recombinant protein medicines intensively
- Non-clinical studies of 2 new drugs will begin in 2021 according to pipeline's progress

[Biomedicine Pipelines]

(Apr, 2021)

Group	Indication	Pipe Line	Discovery	Non-clinical	Clinical PI	Clinical PII	Clinical PIII	
New Peptide Drug	Short Bowel Syndrome (SBS)	HL05 (modified GLP2)	→ 21' 3Q Non-clinical (Tox.)					
	Obesity	HL06 (GLP1/Glucagon)	→					
New Protein Drug	Drug Adjuvant	HL04 (rhHyaluronidase)	→ 22' 1Q Non-clinical (Tox.)					
	Fibrosis (Skin)	HL10 (rh-protease)	→					
	Fibrosis (Skin)	HL11 (Complex drug)	→					
	Breast Cancer (TNBC)	HL12 (Bifunctional Ab)	→					
Biosimilar	Osteoporosis	HL03 (Denosumab)	→ 22' 2Q Non-clinical (Tox.)					

Consolidated Financial Information

(Unit: Million KRW)

Classification	2021.1Q	2020
Assets		
Current assets	406,589	427,322
Non-current assets	572,634	521,700
Total Assets	979,223	949,023
Liabilities		
Current liabilities	262,519	237,373
Non-current liabilities	57,331	56,251
Total liabilities	319,851	293,624
Equity		
Dominant business owner's equity	413,900	412,828
Non-controlling interests	245,472	242,570
Total equity	659,372	655,399
Total equity and liabilities	979,223	949,023

Classification	2021.1Q	2020
Revenue(Sales)	131,643	523,048
Cost of sales	111,101	433,799
Operating Income	20,542	89,249
Profit(loss) before tax	19,649	111,793
Corporate tax	3,925	20,750
Net income	15,724	91,043

Separate Financial Information

(Unit: Million KRW)

Classification	2021.1Q	2020
Assets		
Current assets	23,018	53,250
Non-current assets	387,331	339,163
Total Assets	410,349	392,414
Liabilities		
Current liabilities	80,451	62,974
Non-current liabilities	5,457	5,436
Total liabilities	85,908	68,409
Equity		
Capital	6,015	5,732
Capital surplus	242,472	242,472
Capital adjustment	(12,789)	(11,029)
Earned surplus	88,743	86,829
Total equity	324,441	324,004
Total equity and liabilities	410,349	392,414

Classification	2021.1Q	2020
Revenue(Sales)	14,617	41,867
Cost of sales	7,909	26,797
Operating Income	6,708	15,070
Profit(loss) before tax	7,426	16,878
Corporate tax	700	2,072
Net income	6,726	14,807

Thank you